iECURE to Present Clinical Data from Ongoing OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at SSIEM Annual Symposium

Go back to iECURE to Present Clinical Data from Ongoing OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at SSIEM Annual Symposium
(NASDAQ: DTIL) Delayed: 6.78 --0 (-0%)
Previous Close $6.78    52 Week High $ 
Open $6.78    52 Week Low $ 
Day High $6.78    P/E N/A 
Day Low $6.78    EPS $ 
Volume 2